Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
Alaunos Therapeutics acquired Velaris and raised $350 million to advance clinical therapies for pulmonary arterial hypertension through 2029.
Share
Why It Matters
Alaunos bought another company and raised lots of money for research. This shows the company is investing heavily in new treatments.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.